Adagio Therapeutics CEO Tillman Gerngross has agreed "in principle" to resign as head of the COVID-19 drug developer amid confusion over whether its most advanced antibody treatment works against the omicron variant.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,